0000000000291531

AUTHOR

Margitta Worm

showing 19 related works from this author

Mast cells as initiators of immunity and host defense

2001

Until recently, mast cells have been viewed primarily as harmful because of their key role as effector cells of allergic and potentially lethal anaphylactic reactions. Their contribution to human health appeared instead to be limited to the elimination of parasites. There is, however, growing evidence for additional beneficial functions of mast cells, particularly regarding the initiation of acquired immune reactions. Thus, mast cells can phagocytize diverse particles, take up antigens, and express a number of receptors, particularly MHC class I and II antigens, ICAM-1 and -3, CD43, CD80, CD86 and CD40L which allow them to interact with T and B lymphocytes. They can also secrete numerous cy…

0303 health sciencesInnate immune systembiologyDegranulationchemical and pharmacologic phenomenaDermatologyImmunoglobulin EAcquired immune systemMast cellBiochemistry3. Good healthInterleukin 3303 medical and health sciencesClassical complement pathway0302 clinical medicineImmune systemmedicine.anatomical_structureImmunologybiology.proteinmedicineMolecular Biology030304 developmental biology030215 immunologyExperimental Dermatology
researchProduct

Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model

2021

International audience; The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to dete…

Allergen immunotherapyEndotypeMESH: AllergensMESH: HypersensitivityImmunologyDiseaseBioinformaticsMESH: Precision Medicine03 medical and health sciences0302 clinical medicinemolecular diagnosisHypersensitivityImmunology and AllergyMedicineHumansPrecision MedicineMESH: Desensitization Immunologic[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyMESH: Humansbusiness.industryMechanism (biology)MESH: GenomicsGenomicspersonalized medicineAllergenstreatable traitsMolecular diagnosticsOmics3. Good healthBiomarker (cell)omicsallergen immunotherapy; molecular diagnosis; omics; personalized medicine; treatable traits030228 respiratory systemDesensitization Immunologicallergen immunotherapyPersonalized medicinebusiness[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology030215 immunology
researchProduct

15. Mainzer Allergie-Workshop 2003

2003

030207 dermatology & venereal diseases03 medical and health sciencesmedicine.medical_specialty0302 clinical medicine030228 respiratory systemOtorhinolaryngologybusiness.industryFamily medicinemedicineImmunology and AllergybusinessAllergo Journal
researchProduct

S3 Guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 2

2019

Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed-type hypersensitivity. The target audience also includes other health care providers and insurance funds. Based on a systematic literature search and a formal consensus process (S3), the guidelines were developed by dermatologists in collaboration with pediatricians, occupational medicine physici…

Occupational Medicinemedicine.medical_specialtyConsensusMEDLINETarget audienceDermatologyOccupational medicineImmunocompromised Host030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePregnancyHealth caremedicineHumansHypersensitivity DelayedPediatriciansChildAdverse effectAllergic contact dermatitisbusiness.industryAllergensPatch Testsmedicine.disease3. Good healthTest (assessment)Family medicineDermatitis Allergic ContactPractice Guidelines as TopicFemaleNursing StaffbusinessContact dermatitisDermatologistsJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Patch testing in children--recommendations of the German Contact Dermatitis Research Group (DKG).

2007

Summary Allergic contact dermatitis occurs frequently in children. Patch testing is needed to identify the responsible allergens and should be performed in children. We recommend a panel of 12 contact allergens as a standard series in children from 6–12 years. Four additional contact allergens should be tested in case of a positive history or suggestive clinical picture. For patch testing in children, the allergens should be applied for 24 hours and the readings should be performed at 48 and 72 hours. Standardized patch testing makes it possible to systematically investigate allergic contact dermatitis and identify relevant allergens in children.

medicine.medical_specialtyDermatitisDermatologyPediatricsPatch testing030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineimmune system diseases030225 pediatricsGermanyotorhinolaryngologic diseasesmedicineHumansContact allergensPractice Patterns Physicians'Allergic contact dermatitisbusiness.industryrespiratory systemPatch Testsmedicine.diseaseDermatologyrespiratory tract diseases3. Good healthDermatitis Allergic ContactPractice Guidelines as TopicbusinessContact dermatitisJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct

Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie – ein Positionspapier von ARIA, EAACI, AeDA, GPA und DGAKI (Kurzversion) – Positionspapier …

2020

Allergen immunotherapyCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030228 respiratory systemOtorhinolaryngologyDermatology clinicPandemicImmunologyPosition paperMedicinebusinessCoronavirus InfectionsLaryngo-Rhino-Otologie
researchProduct

Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCL…

2012

In this prospective, cross-sectional, multicenter study, we assessed clinical and laboratory characteristics from patients with cutaneous lupus erythematosus (CLE) using the Core Set Questionnaire of the European Society of Cutaneous Lupus Erythematosus (EUSCLE). 1002 (768 females, 234 males) patients with different subtypes of CLE, such as acute CLE (ACLE, 304 patients), subacute CLE (SCLE, 236 patients), chronic CLE (CCLE, 397 patients), and intermittent CLE (ICLE, 65 patients), from 13 European countries were collected and statistically analyzed by an SPSS database. The main outcome measures included gender, age at onset of disease, LE-specific and LE-nonspecific skin lesions, photosensi…

AdultMalemedicine.medical_specialtyPathologyDatabases FactualAnti-nuclear antibodyCross-sectional studyImmunologyDiseaseDiagnosis Differential030207 dermatology & venereal diseases03 medical and health sciencesSex Factors0302 clinical medicineSurveys and QuestionnairesInternal medicineLupus Erythematosus CutaneousmedicineHumansImmunology and AllergyProspective StudiesAge of OnsetGeography MedicalProspective cohort studyAgedSkin030203 arthritis & rheumatologyAutoimmune diseaseLupus erythematosusbusiness.industryfungiAge FactorsMiddle Agedmedicine.diseaseDermatologyRheumatology3. Good healthEuropeCross-Sectional StudiesFemaleAge of onsetbusinessAutoimmunity Reviews
researchProduct

Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune di…

2015

Bernhard Manger,1 Falk Hiepe,2 Matthias Schneider,3 Margitta Worm,4 Peter Wimmer,5 Eva-Maria Paulus,5 Andreas Schwarting6 1University Hospital Erlangen, Med Clinic III Polyclinic, Erlangen, 2Rheumatology, University Hospital Charité, Campus Mitte, Berlin, 3Policlinic of Rheumatology, Heinrich-Heine-Universität, Düsseldorf, 4Department of Dermatology, Venereology and Allergology, University Hospital Charité, Campus Mitte, Berlin, 5Novartis Pharma GmbH, Nürnberg, 6Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany Background: The purpose of this study was to assess changes in gastrointestinal symptom severity in pati…

medicine.medical_specialtyAbdominal painClinical and Experimental GastroenterologyNauseabusiness.industrymycophenolate mofetilGastroenterologyautoimmune diseaseenteric-coated mycophenolate sodiumpatient-reported outcomeIndigestionhealth-related quality of lifeQuality of lifeRating scaleInternal medicineClinical endpointmedicinePatient-reported outcomemedicine.symptomAdverse effectbusinessOriginal ResearchClinical and Experimental Gastroenterology
researchProduct

In-vitro-Allergiediagnostik

2010

medicine.medical_specialtyAllergyOtorhinolaryngologybiologybusiness.industryImmunologymedicinebiology.proteinImmunology and Allergymedicine.diseasebusinessImmunoglobulin EIn vitroAllergo Journal
researchProduct

Keine Empfehlung für IgG- und IgG4-Bestimmungen gegen Nahrungsmittel

2009

030207 dermatology & venereal diseases030201 allergy03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industryImmunology and AllergyMedicinebusinessDermatologyAllergo Journal
researchProduct

BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy.

2016

Background Conflicting results exist on the effect of allergen immunotherapy (AIT) on pollen-related food allergy. We aimed to investigate the efficacy of one-year AIT with the folding variant (FV) of recombinant (r) Bet v 1 on birch-related soya allergy. Methods Of 138 subjects with Bet v 1 sensitization, 82 were positive at double-blind placebo-controlled food challenge (DBPCFC) with soya. A total of 56 of 82 were randomized in the ratio of 2:1 (active: placebo). Per-protocol population (PPP) had received ≥150 μg of allergen or placebo preparation. Outcome measures: lowest observed adverse effect levels (LOAEL), postinterventional occurrence of objective signs (objS) at any dose level, sI…

AdultMaleAllergen immunotherapymedicine.medical_specialtyAllergyImmunologyPopulationmedicine.disease_causePlaceboGastroenterology030207 dermatology & venereal diseases03 medical and health sciencessymbols.namesake0302 clinical medicineAllergenFood allergyStatistical significanceInternal medicinemedicineImmunology and AllergyHumanseducationFisher's exact testBetulaSkin Testseducation.field_of_studybusiness.industryRhinitis Allergic SeasonalAntigens PlantImmunoglobulin EMiddle Agedmedicine.diseaseTreatment Outcome030228 respiratory systemDesensitization ImmunologicImmunologysymbolsQuality of LifeFemaleSoybeansbusinessFood HypersensitivityAllergy
researchProduct

Meat allergy associated with galactosyl‐α‐(1,3)‐galactose (α‐Gal)—Closing diagnostic gaps by anti‐α‐Gal IgE immune profiling

2017

Background Glycoproteins and glycolipids of some mammalian species contain the disaccharide galactosyl-α-(1,3)-galactose (α-Gal). It is known that α-Gal is immunogenic in humans and causes glycan-specific IgG and also IgE responses with clinical relevance. α-Gal is part of the IgE-reactive monoclonal therapeutic antibody cetuximab (CTX) and is associated with delayed anaphylaxis to red meat. In this study, different α-Gal-containing analytes are examined in singleplex and multiplex assays to resolve individual sensitization patterns with IgE against α-Gal. Methods Three serum groups, α-Gal-associated meat allergy (MA) patients, idiopathic anaphylaxis (IA) patients with suspected MA, and non…

AdultMale0301 basic medicineAllergyMeatmedicine.medical_treatmentImmunologyDot blotCross ReactionsImmunoglobulin EArticleYoung Adult03 medical and health sciences0302 clinical medicinemedicineHumansImmunology and AllergyMultiplexAnaphylaxisSensitizationAgedbiologybusiness.industryImmunochemistryGalactoseAllergensImmunoglobulin EMiddle Agedmedicine.diseaseRed Meat030104 developmental biologymedicine.anatomical_structure030228 respiratory systemCase-Control StudiesImmunologyMonoclonalbiology.proteinFemaleThyroglobulinbusinessFood HypersensitivityAnaphylaxisAllergy
researchProduct

Late reactions to patch test preparations with reduced concentrations of p-phenylenediamine : a multicentre investigation of the German Contact Derma…

2011

Background. p-Phenylenediamine (PPD) 1% in petrolatum has been shown in a prospective study to elicit late reactions in 1.5% of routine patch tests, which may be indicative of patch test sensitization. Objectives. To assess the frequency of late reactions to reduced PPD patch test concentrations. Methods. In 1838 patients, PPD was tested at three concentrations (0.5% pet., group I; 0.4% pet., group II; and 0.35% pet., group III). Patch tests were read on D1 (D2) to D3 (D4); additional late readings were performed on D7, D14, and D21. Patients who were not able to return for all scheduled late readings were telephoned on D7, D14, and D21, and questioned about a reaction at the patch test sit…

AdultMalemedicine.medical_specialtyAllergyTime FactorsMedizinDermatologyPhenylenediaminesGastroenterology030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineImmunopathologyInternal medicineImmunology and AllergyMedicineHumans030212 general & internal medicineProspective cohort studySensitizationbusiness.industryPatch testp-PhenylenediamineMiddle AgedPatch Testsmedicine.disease3. Good healthSurgerymedicine.anatomical_structurechemistryPatch test sensitizationDermatitis Allergic ContactFemalebusinessContact dermatitis
researchProduct

Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial

2016

Background: Atopic dermatitis (AD) is a chronic relapsing skin disease prevalent in 1% to 3% of adults in Western industrialized countries. Objective: We sought to investigate the effectiveness of educational training in an outpatient setting on coping with the disease, quality of life, symptoms, and severity in adults with AD. Methods: In this German prospective, randomized controlled multicenter study, adult patients with moderate-to-severe AD were educated by referring to a comprehensive 12-hour training manual consented by a multiprofessional study group from different centers (Arbeitsgemeinschaft Neurodermitisschulung fur Erwachsene [ARNE]). Patients were randomly allocated to the inte…

AdultMaleCoping (psychology)medicine.medical_specialtyImmunologyDiseaseSeverity of Illness IndexDermatitis Atopiclaw.inventionYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePatient Education as TopicRandomized controlled triallawAdaptation PsychologicalmedicineHumansImmunology and Allergy030212 general & internal medicinebusiness.industrySocial anxietyAtopic dermatitisMiddle Agedmedicine.diseaseQuality of LifePhysical therapyItchingFemalemedicine.symptombusinessPsychosocialPatient educationJournal of Allergy and Clinical Immunology
researchProduct

Management of anaphylaxis due to COVID-19 vaccines in the elderly

2021

Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffab…

MaleAllergyPediatricsEaaci Position PaperCOVID-19 vaccinesolder (adultsGUIDELINES0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesMedicine and Health SciencesImmunology and AllergyMedicine030212 general & internal medicineComputingMilieux_MISCELLANEOUSGeriatricsMESH: AgedRISKVaccines[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasespeople)EPINEPHRINEEpinephrine[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCOVID -19 vaccinesAnaphylaxismedicine.drugolder (adults/people)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)MESH: Covid-19MESH: EpinephrineImmunologyadrenaline; anaphylaxis; COVID-19 vaccines; older (adults/people); Aged; COVID-19 Vaccines; Epinephrine; Humans; Male; SARS-CoV-2; Anaphylaxis; COVID-19Settore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemDiabetes mellitusAnaphylaxis/etiologyanaphylaxisHumansMESH: SARS-CoV-2[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyCOVID‐19 vaccinesOlder - Adults/peopleAsthmaAgedMESH: Humansadrenalinebusiness.industrySARS-CoV-2adrenaline anaphylaxis COVID-19 vaccines older (adults/people)COVID-19medicine.diseaseObesity[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyMESH: MaleMESH: AnaphylaxisOlder3121 General medicine internal medicine and other clinical medicinebusinessMESH: Covid-19 vaccines030215 immunologyAllergy
researchProduct

A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-con…

2021

Background: Allergic rhinitis induced by house dust mites (HDMs) is a highly prevalent but often underdiagnosed and undertreated/untreated chronic disease. It often has a negative impact on sleep, work, leisure activities, and health-related quality of life. Allergen immunotherapy is a proven, safe treatment for respiratory allergies. Objective: We sought to assess the efficacy and safety of a 300 index of reactivity (IR) sublingual tablet formulation of Dermatophagoides pteronyssinus:Dermatophagoides farinae 1:1 extract in adolescents (aged >_12) and adults with moderate to severe HDM-induced allergic rhinitis. Methods: In a phase III, international, double-blind, placebo controlled, rando…

0301 basic medicineAllergen immunotherapy; allergic rhinitis; allergy; house-dust mite; medication score; sublingual immunotherapy; symptom score; tablet; total combined scoreMaleAllergyInternational Cooperation*total combined scoreSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallaw*allergyClinical endpointImmunology and Allergy[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergologyhouse dust miteAllergen immunotherapybiologyPyroglyphidae*tablet*allergic rhinitis*sublingual immunotherapy3. Good healthhouse-dust mitetotal combined score*Allergen immunotherapyFemale[SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology*medication scoreAdultAllergen immunotherapymedicine.medical_specialtyAdolescentDrug-Related Side Effects and Adverse ReactionsImmunologyPlacebosublingual immunotherapymedication score03 medical and health sciencesYoung AdultDouble-Blind MethodInternal medicinemedicineAnimalsHumansAntigens DermatophagoidesAsthmaHouse dust mitetabletSublingual Immunotherapyallergic rhinitisbusiness.industry[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapymedicine.diseasebiology.organism_classificationallergyPlacebo EffectRhinitis Allergic*symptom scoresymptom scoreClinical trial030104 developmental biology030228 respiratory system*house-dust miteQuality of LifebusinessThe Journal of allergy and clinical immunology
researchProduct

Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICP…

2016

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adu…

Pulmonary and Respiratory MedicineGerontologyAllergen immunotherapymedicine.medical_specialtyAllergyAl·lèrgiaEIP on AHAAllergy[SDV]Life Sciences [q-bio]ImmunologyAlternative medicineImmunoteràpiaReview03 medical and health sciences0302 clinical medicinemedicineJournal ArticleImmunology and Allergy030212 general & internal medicineAsthmaAllergen immunotherapyRhinitisbusiness.industryPrecision medicinemedicine.diseaseAsthma3. Good healthIntegrated care[SDV] Life Sciences [q-bio]AgeingAIRWAYS ICPs030228 respiratory systemGeneral partnershipAction planImmunologyImmunotherapybusiness
researchProduct

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

2019

Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed-type hypersensitivity. The target audience also includes other health care providers and insurance funds. Based on a systematic literature search and a formal consensus process (S3), the guidelines were developed by dermatologists in collaboration with pediatricians, occupational medicine physici…

Occupational Medicinemedicine.medical_specialtyConsensusMEDLINETarget audienceGuidelines as TopicDermatologyPatch testingOccupational medicineImmunocompromised Host030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePregnancyHealth caremedicineHumansHypersensitivity DelayedPediatriciansChildAllergic contact dermatitisbusiness.industryAllergensPatch Testsmedicine.diseaseTest (assessment)Family medicineDermatitis Allergic ContactFemaleNursing StaffbusinessContact dermatitisDermatologistsJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

17. Mainzer Allergie-Workshop

2005

medicine.medical_specialtyOtorhinolaryngologybusiness.industryFamily medicinemedicineImmunology and AllergybusinessAllergo Journal
researchProduct